nach oben

Cancer Causes & Control

Erschienen in:

06.09.2024 | Original Paper

Sleep and cancer mortality in the Cancer Prevention Study-II

verfasst von: Sidney M. Donzella, Emily Deubler, Alpa V. Patel, Amanda I. Phipps, Charlie Zhong

Erschienen in: Cancer Causes & Control | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Sleep is a multi-dimensional human function that is associated with cancer outcomes. Previous work on sleep and cancer mortality have not investigated how this relationship varies by sex and cancer site. We investigated the association of sleep duration and perceived insomnia with site-specific and overall cancer mortality among participants in the Cancer Prevention Study–II.

Methods

Sleep was collected at baseline in 1982 among 1.2 million cancer-free US adults. Cancer-specific mortality was determined through 2018. We used multivariable Cox proportional hazard models to calculate hazard ratios and 95% confidence intervals for overall and site-specific cancer mortality, stratified by sex.

Results

Among 983,105 participants (56% female) followed for a median of 27.9 person-years, there were 146,911 primary cancer deaths. Results from the adjusted model showed short (6 h/night) and long (8 h/night and 9–14 h/night) sleep duration, compared to 7 h/night, were associated with a modest 2%, 2%, and 5% higher risk of overall cancer mortality, respectively, and there was a significant non-linear trend (p-trend < 0.01). This non-linear trend was statistically significant among male (p-trend < 0.001) but not female (p-trend 0.71) participants. For male participants, short and long sleep were associated with higher risk of lung cancer mortality and long sleep was associated with higher risk of colorectal cancer mortality. Perceived insomnia was associated with a 3–7% lower risk of overall cancer mortality.

Conclusion

Sleep is important to consider in relation to sex- and site-specific cancer mortality. Future research should investigate other components of sleep in relation to cancer mortality.

Nur mit Berechtigung zugänglich

Hirshkowitz M, Whiton K, Albert SM et al (2015) National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep Health 1(1):40–43PubMed

Panel CC, Watson NF, Badr MS et al (2015) Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. J Clin Sleep Med 11(6):591–592

Ford ES, Cunningham TJ, Croft JB (2015) Trends in self-reported sleep duration among US adults from 1985 to 2012. Sleep 38(5):829–832PubMedPubMedCentral

Roth T (2007) Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 3(5 suppl):S7–S10PubMedPubMedCentral

Baron KG, Reid KJ (2014) Circadian misalignment and health. Int Rev Psychiatry 26(2):139–154PubMedPubMedCentral

Stone CR, Haig TR, Fiest KM, McNeil J, Brenner DR, Friedenreich CM (2019) The association between sleep duration and cancer-specific mortality: a systematic review and meta-analysis. Cancer Causes Control 30(5):501–525PubMed

Gallicchio L, Kalesan B (2009) Sleep duration and mortality: a systematic review and meta-analysis. J Sleep Res 18(2):148–158PubMed

Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR (2002) Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 59(2):131–136PubMed

Guo X, Zheng L, Wang J et al (2013) Epidemiological evidence for the link between sleep duration and high blood pressure: a systematic review and meta-analysis. Sleep Med 14(4):324–332PubMed

10.

Itani O, Jike M, Watanabe N, Kaneita Y (2017) Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. Sleep Med 32:246–256PubMed

11.

Carter BD, Diver WR, Hildebrand JS, Patel AV, Gapstur SM (2014) Circadian disruption and fatal ovarian cancer. Am J Prev Med 46(3):S34–S41PubMed

12.

Gapstur SM, Diver WR, Stevens VL, Carter BD, Teras LR, Jacobs EJ (2014) Work schedule, sleep duration, insomnia, and risk of fatal prostate cancer. Am J Prev Med 46(3):S26–S33PubMed

13.

Rod NH, Vahtera J, Westerlund H et al (2011) Sleep disturbances and cause-specific mortality: results from the GAZEL cohort study. Am J Epidemiol 173(3):300–309PubMed

14.

Sillah A, Watson NF, Peters U et al (2022) Sleep problems and risk of cancer incidence and mortality in an older cohort: the Cardiovascular Health Study (CHS). Cancer Epidemiol 76:102057PubMed

15.

Tao F, Cao Z, Jiang Y et al (2021) Associations of sleep duration and quality with incident cardiovascular disease, cancer, and mortality: a prospective cohort study of 407,500 UK biobank participants. Sleep Med 81:401–409PubMed

16.

Garfinkel L (1959) Selection, follow-up, and analysis in the American Cancer Society prospective studies¹. National Cancer Institute Monograph, p 49

17.

Organization WH (1978) International classification of diseases: [9th] ninth revision, basic tabulation list with alphabetic index. World Health Organization, Geneva

18.

Organization WH (2004) International statistical classification of diseases and related health problems: alphabetical index, vol 3. World Health Organization, Geneva

19.

Jacobs EJ, Newton CC, Wang Y, Campbell PT, Flanders WD, Gapstur SM (2018) Ghost-time bias from imperfect mortality ascertainment in aging cohorts. Ann Epidemiol 28(10):691–696. e3PubMed

20.

Cai H, Shu X-O, Xiang Y-B et al (2015) Sleep duration and mortality: a prospective study of 113,138 middle-aged and elderly Chinese men and women. Sleep 38(4):529–536PubMedPubMedCentral

21.

Åkerstedt T, Bellocco R, Widman L et al (2023) The association of short and long sleep with mortality in men and women. J Sleep Res 33:e13931PubMed

22.

Blask DE (2009) Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 13(4):257–264PubMed

23.

Irwin MR, Wang M, Ribeiro D et al (2008) Sleep loss activates cellular inflammatory signaling. Biol Psychiatry 64(6):538–540PubMedPubMedCentral

24.

Irwin MR, Carrillo C, Olmstead R (2010) Sleep loss activates cellular markers of inflammation: sex differences. Brain Behav Immun 24(1):54–57PubMed

25.

Prather AA, Vogelzangs N, Penninx BW (2015) Sleep duration, insomnia, and markers of systemic inflammation: results from the Netherlands Study of Depression and Anxiety (NESDA). J Psychiatr Res 60:95–102PubMed

26.

Irwin MR, Olmstead R, Carroll JE (2016) Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry 80(1):40–52PubMed

27.

Singh-Manoux A, Shipley MJ, Bell JA, Canonico M, Elbaz A, Kivimäki M (2017) Association between inflammatory biomarkers and all-cause, cardiovascular and cancer-related mortality. Cand Med Assoc J 189(10):E384–E390

28.

Wong JY, Bassig BA, Vermeulen R et al (2017) Sleep duration across the adult lifecourse and risk of lung cancer mortality: a cohort study in Xuanwei, China. Cancer Prev Res 10(6):327–336

29.

Jaehne A, Unbehaun T, Feige B, Lutz UC, Batra A, Riemann D (2012) How smoking affects sleep: a polysomnographical analysis. Sleep Med 13(10):1286–1292PubMed

30.

Shopland DR (1995) Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect 103(suppl 8):131–142PubMedPubMedCentral

31.

Zhang L, Samet J, Caffo B, Punjabi NM (2006) Cigarette smoking and nocturnal sleep architecture. Am J Epidemiol 164(6):529–537PubMed

32.

Marinac CR, Nelson SH, Flatt SW, Natarajan L, Pierce JP, Patterson RE (2017) Sleep duration and breast cancer prognosis: perspectives from the Women’s Healthy Eating and Living Study. Breast Cancer Res Treat 162:581–589PubMedPubMedCentral

33.

Wu T, Zou Y, Xu K et al (2023) Insomnia and multiple health outcomes: umbrella review of meta-analyses of prospective cohort studies. Public Health 215:66–74PubMed

34.

Hakim F, Wang Y, Zhang SX et al (2014) Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling disrupted sleep and cancer. Cancer Res 74(5):1329–1337PubMedPubMedCentral

35.

Parthasarathy S, Vasquez MM, Halonen M et al (2015) Persistent insomnia is associated with mortality risk. Am J Med 128(3):268–275. e2PubMed

36.

Harvey A, Scott H, Melaku YA et al (2023) The mortality risk of night-time and daytime insomnia symptoms in an older population. Sci Rep 13(1):9575. https://doi.org/10.1038/s41598-023-36016-4CrossRefPubMedPubMedCentral

37.

Gu F, Xiao Q, Chu LW et al (2016) Sleep duration and cancer in the NIH-AARP diet and health study cohort. PLoS ONE 11(9):e0161561PubMedPubMedCentral

38.

Jiao L, Duan Z, Sangi-Haghpeykar H, Hale L, White D, El-Serag H (2013) Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer 108(1):213–221PubMedPubMedCentral

39.

Hurley S, Goldberg D, Bernstein L, Reynolds P (2015) Sleep duration and cancer risk in women. Cancer Causes Control 26(7):1037–1045PubMedPubMedCentral

40.

Hu L, Harper A, Heer E et al (2020) Social jetlag and prostate cancer incidence in Alberta’s Tomorrow Project: a prospective cohort study. Cancers 12(12):3873PubMedPubMedCentral

41.

McNeil J, Barberio AM, Friedenreich CM, Brenner DR (2019) Sleep and cancer incidence in Alberta’s Tomorrow Project cohort. Sleep 42(3):zsy252PubMed

42.

Dillon HR, Lichstein KL, Dautovich ND, Taylor DJ, Riedel BW, Bush AJ (2015) Variability in self-reported normal sleep across the adult age span. J Gerontol B 70(1):46–56

43.

Kocevska D, Lysen TS, Dotinga A et al (2021) Sleep characteristics across the lifespan in 1.1 million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis. Nat Hum Behav 5(1):113–122PubMed

44.

Roenneberg T, Pilz LK, Zerbini G, Winnebeck EC (2019) Chronotype and social jetlag: a (self-) critical review. Biology 8(3):54PubMedPubMedCentral

45.

Evans MA, Buysse DJ, Marsland AL et al (2021) Meta-analysis of age and actigraphy-assessed sleep characteristics across the lifespan. Sleep 44(9):zsab088PubMedPubMedCentral

46.

Roenneberg T, Wirz-Justice A, Merrow M (2003) Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms 18(1):80–90PubMed

47.

Sabia S, Fayosse A, Dumurgier J et al (2021) Association of sleep duration in middle and old age with incidence of dementia. Nat Commun 12(1):2289PubMedPubMedCentral

48.

Thorleifsdottir B, Björnsson J, Benediktsdottir B, Gislason T, Kristbjarnarson H (2002) Sleep and sleep habits from childhood to young adulthood over a 10-year period. J Psychosom Res 53(1):529–537PubMed

49.

Zeitlhofer J, Schmeiser-Rieder A, Tribl G et al (2000) Sleep and quality of life in the Austrian population. Acta Neurol Scand 102(4):249–257PubMed

50.

Steiger A, Pawlowski M (2019) Depression and sleep. Int J Mol Sci 20(3):607PubMedPubMedCentral

51.

Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115(22):5349–5361PubMed

52.

Luojus MK, Lehto SM, Tolmunen T, Erkkilä AT, Kauhanen J (2014) Sleep duration and incidence of lung cancer in ageing men. BMC Public Health 14(1):1–7

53.

Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66(10):5521–5525PubMed

54.

Palesh O, Aldridge-Gerry A, Zeitzer JM et al (2014) Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep 37(5):837–842PubMedPubMedCentral

Titel: Sleep and cancer mortality in the Cancer Prevention Study-II
verfasst von: Sidney M. Donzella
Emily Deubler
Alpa V. Patel
Amanda I. Phipps
Charlie Zhong
Publikationsdatum: 06.09.2024
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 12/2024
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-024-01910-3

Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia

Original Paper

Prostate-specific antigen testing patterns and prostate cancer stage at diagnosis in older Ohio cancer patients

Open Access
Original Paper

Body mass index and the prevalence of high-risk colorectal adenomas in a population undergoing screening colonoscopy in Alberta, Canada

Original Paper

The association between food insecurity and colorectal cancer screening: 2018–2021 New York State Behavioral Risk Factor Surveillance System (BRFSS)

Original Paper

Indigenous access to clinical services along the lung cancer treatment pathway: a review of current evidence

Open Access
Review article

Is there an association between mastitis and breast cancer? a retrospective cohort study from Germany

Open Access
Original Paper

Neu im Fachgebiet Onkologie

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

15.01.2025
Akute myeloische Leukämie
Nachrichten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

14.01.2025
Nierenkarzinom
Nachrichten

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Sleep and cancer mortality in the Cancer Prevention Study-II